Corient Private Wealth LLC Sells 633 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Corient Private Wealth LLC trimmed its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWRFree Report) by 1.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 41,386 shares of the biotechnology company’s stock after selling 633 shares during the period. Corient Private Wealth LLC’s holdings in Arrowhead Pharmaceuticals were worth $1,266,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. UBS Group AG increased its holdings in Arrowhead Pharmaceuticals by 37.6% in the fourth quarter. UBS Group AG now owns 508,586 shares of the biotechnology company’s stock valued at $15,563,000 after purchasing an additional 138,984 shares during the period. Norges Bank acquired a new stake in Arrowhead Pharmaceuticals in the fourth quarter valued at $40,451,000. Vanguard Personalized Indexing Management LLC acquired a new stake in Arrowhead Pharmaceuticals in the fourth quarter valued at $309,000. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in Arrowhead Pharmaceuticals by 12.3% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 8,714 shares of the biotechnology company’s stock valued at $279,000 after purchasing an additional 952 shares during the period. Finally, BNP Paribas Financial Markets grew its holdings in Arrowhead Pharmaceuticals by 13.6% during the 4th quarter. BNP Paribas Financial Markets now owns 243,605 shares of the biotechnology company’s stock worth $7,454,000 after acquiring an additional 29,124 shares during the period. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Stock Performance

Shares of NASDAQ ARWR opened at $22.95 on Monday. Arrowhead Pharmaceuticals, Inc. has a fifty-two week low of $20.67 and a fifty-two week high of $39.83. The stock has a market cap of $2.85 billion, a price-to-earnings ratio of -5.40 and a beta of 0.78. The firm’s 50-day simple moving average is $24.67 and its 200 day simple moving average is $28.52.

Arrowhead Pharmaceuticals (NASDAQ:ARWRGet Free Report) last announced its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.96). Arrowhead Pharmaceuticals had a negative net margin of 163.32% and a negative return on equity of 140.72%. During the same quarter in the prior year, the firm posted $0.45 earnings per share. The company’s revenue for the quarter was down 100.0% on a year-over-year basis. On average, sell-side analysts predict that Arrowhead Pharmaceuticals, Inc. will post -3.05 EPS for the current year.

Insiders Place Their Bets

In other Arrowhead Pharmaceuticals news, CFO Kenneth Allen Myszkowski sold 40,000 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $35.19, for a total transaction of $1,407,600.00. Following the transaction, the chief financial officer now owns 400,600 shares of the company’s stock, valued at approximately $14,097,114. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Arrowhead Pharmaceuticals news, CFO Kenneth Allen Myszkowski sold 40,000 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $35.19, for a total transaction of $1,407,600.00. Following the transaction, the chief financial officer now owns 400,600 shares of the company’s stock, valued at approximately $14,097,114. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Hongbo Lu bought 1,000 shares of the company’s stock in a transaction on Monday, March 18th. The shares were purchased at an average cost of $27.49 per share, for a total transaction of $27,490.00. Following the transaction, the director now owns 31,680 shares in the company, valued at $870,883.20. The disclosure for this purchase can be found here. Insiders own 4.50% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $90.00 price target on shares of Arrowhead Pharmaceuticals in a report on Monday, May 13th. Royal Bank of Canada reiterated an “outperform” rating and set a $50.00 price target on shares of Arrowhead Pharmaceuticals in a report on Wednesday, February 7th. Chardan Capital restated a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Friday, May 10th. Citigroup raised their target price on Arrowhead Pharmaceuticals from $33.00 to $34.00 and gave the company a “neutral” rating in a research note on Wednesday, February 7th. Finally, Morgan Stanley reduced their target price on Arrowhead Pharmaceuticals from $36.00 to $27.00 and set an “equal weight” rating for the company in a research note on Monday, May 13th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $50.00.

Check Out Our Latest Analysis on Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals Profile

(Free Report)

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

Read More

Institutional Ownership by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.